HERON THERAPEUTICS, INC. /DE/ (HRTX) — SEC Financial Statements & Analysis

HERON THERAPEUTICS, INC. /DE/ (HRTX) is a pharmaceutical preparations company, incorporated in DE. HERON THERAPEUTICS, INC. /DE/ trades on Nasdaq as: HRTX. HERON THERAPEUTICS, INC. /DE/ (HRTX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-10. Based on that filing, HERON THERAPEUTICS, INC. /DE/ carries a market cap of $81.84M, a P/E ratio of -2.40x, a P/B ratio of 11.85x, a P/S ratio of 0.54x, an enterprise value of $95.05M, and an EV/EBITDA multiple of -10.89x. On profitability, it posts a gross margin of 70.07%, an operating margin of -7.19%, a net margin of -22.52%, a Return on Equity (ROE) of 334.63%, a Return on Assets (ROA) of -14.06%, and a Return on Invested Capital (ROIC) of -16.44%. Per share, it reports EPS of $-0.18, diluted EPS of $-0.18, free cash flow per share of $-0.06, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 0.99% year-over-year, net income growth of 3557.25% year-over-year, and EPS growth of 2859.46% year-over-year. On the balance sheet, it maintains a current ratio of 2.49x, a quick ratio of 1.44x, working capital of $137.70M, a debt-to-equity ratio of 35.52x, a debt ratio of 0.97, free cash flow of $-12.13M (TTM), and net debt of $13.20M. Figures sourced from SEC EDGAR.

Market Cap

$81.84M

P/E TTM

-2.40x

EPS TTM

$-0.18

P/B TTM

11.85x

ROE TTM

334.63%

ROA TTM

-14.06%

Debt To Equity

35.52x

Free Cash Flow TTM

$-12.13M

Net Revenue TTM Growth 1Y

0.99%

Data as of 2026-06-30 · Source: SEC EDGAR